ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

4:00PM-4:15PM: Abstract Number: 1460

Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry

Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)

4:00PM-4:15PM: Abstract Number: 1454

RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

4:15PM-4:30PM: Abstract Number: 1461

Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis

Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)

4:15PM-4:30PM: Abstract Number: 1455

IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

4:15PM-4:30PM: Abstract Number: 1465

Trends in Adverse Pregnancy Outcomes Among Women with Systemic Sclerosis in the United States

Abstracts: Reproductive Issues in Rheumatic Disorders (1464–1467)

4:30PM-4:45PM: Abstract Number: 1456

Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

4:30PM-4:45PM: Abstract Number: 1462

Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares

Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)

4:30PM-4:45PM: Abstract Number: 1466

Increased Adverse Maternal Postpartum Outcomes in Systemic Lupus Erythematosus Pregnancies Compared to Controls

Abstracts: Reproductive Issues in Rheumatic Disorders (1464–1467)

4:45PM-5:00PM: Abstract Number: 1457

Clinical Heterogeneity of the VEXAS Syndrome: A Case Series

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

4:45PM-5:00PM: Abstract Number: 1467

Determinants of Cervical Cancer Screening Patterns Among Women with Systemic Lupus Erythematosus

Abstracts: Reproductive Issues in Rheumatic Disorders (1464–1467)

4:45PM-5:00PM: Abstract Number: 1463

Use of Telemedicine for Follow-up of Lupus Nephritis in the COVID-19 Outbreak: The 6-month Results of a Randomized Controlled Trial

Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].